• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Role of rTMS in Poststroke Depression

The Role of rTMS in Poststroke Depression

January 7, 2022
Susan L. Siegfreid, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Susan L. Siegfreid, MD Dr. Siegfreid has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Hordacre B et al, J Neurol 2021;268(4):1474–1484

STUDY TYPE: Randomized controlled trial

Poststroke depression is common, disabling, and often treatment refractory. We know repetitive transcranial magnetic stimulation (rTMS) is effective for treatment-resistant depression. Might it offer a safe and effective treatment for poststroke depression? Two previous small randomized controlled trials of rTMS (using high-frequency [10 Hz] delivery of 1,000 pulses per session to the left dorsolateral prefrontal cortex for 10 sessions) demonstrated both safety and efficacy in poststroke depression (Gu SY and Chang MC, Brain Stimul 2017;10(2):270–274; Jorge RE et al, Biol Psychiatry 2004;55(4):398–405). Researchers in the current study hypothesized that delivery of a higher dose—3,000 pulses per session—would increase clinical benefit without compromising safety.

The study recruited 11 patients with moderate (baseline PHQ-9 score > 5) poststroke depression and no change in antidepressant medication for the prior six months. Most of the patients (n = 9) were male, ages 44–78 years, with predominantly right hemispheric strokes occurring one to 11 years prior to enrollment. Participants were randomized to either active (n = 6) or sham (n = 5) rTMS groups using an identical figure-8 coil. They received 10 treatment sessions, occurring over five weekdays for two consecutive weeks. The primary outcome measure for depression severity was the Beck Depression Inventory-II (BDI), which was assessed at baseline, immediately after treatment, and at one month follow-up.

From baseline to one-month follow-up, the BDI scores in the treatment group decreased significantly more than in the sham group, with an average change of 12 points (p = 0.04). Adverse effects were transient and comparable between the treatment and sham groups.

CHPR’S TAKE
This study was small and only followed moderately depressed patients for one month after treatment, but it provides additional evidence that higher-dose rTMS is a safe and effective treatment option for poststroke depression in patients who do not fully respond to antidepressant medication.
Hospital Psychiatry
KEYWORDS depression post-stroke-depression rtms stroke tms transcranial-magnetic-stimulation treatment
Susan L. Siegfreid, MD

Trazodone Probably Not Effective for Dementia

More from this author
www.thecarlatreport.com
Issue Date: January 7, 2022
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Testifying, CHPR, January/February/March 2022
A Primer for Psychiatrists on Court Hearings
Borderline Personality Disorder in the ED
Tarasoff: Making Sense of the Duty to Warn or Protect
Principles of Verbal De-Escalation
Minimizing PTSD From Workplace Trauma
The Role of rTMS in Poststroke Depression
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.